Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

Jian Li(Guangdong University of Technology), Lin Shen(Peking University), Quanli Gao(Zhengzhou University), Ying Yuan(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yaling Xu(Wuhan Sixth Hospital), Ye Xu(Central South University of Forestry and Technology), Aimin Zang(Affiliated Hospital of Hebei University), Yunong Gao, Jing Wang(Qingdao University), Dong Wang(Chongqing University), Tianshu Liu(Sun Yat-sen University), Jianming Xu(Chinese PLA General Hospital), Yidi Wang(Zhongshan People's Hospital), Cong Fei(New York University), Yanqiao Zhang(Harbin Medical University), Haiping Jiang, Yanhong Deng(Sun Yat-sen University), Chunmei Shi(Fujian Medical University), Yi Huang(Hubei Cancer Hospital)
Journal of Clinical Oncology
January 19, 2022
10.1200/jco.2022.40.4_suppl.001
Cited by 5

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775